\-\ Texto\\:\\ \ \(0\)\
\-\ h\\/h\\:\\ 13\\.1\\/39\\.5\\ \\(low\\)\ \(0\)\
\-\ chem\\ panel\\ normal\ \(0\)\
\-\ lfts\\ normal\ \(0\)\
\-\ amylase\\/lipase\\ normal\ \(1\)\
\-\ patient\\ received\\ an\\ egd\\ which\\ demonstrated\\ a\\ large\\,\\ fungating\\ mass\\ in\\ the\\ lower\\ third\\ of\\ the\\ esophagus\\.\\ the\\ mass\\ was\\ partially\\ obstructing\\ and\\ circumferential\\ involving\\ two\\ thirds\\ of\\ the\\ lumen\\.\\ this\\ mass\\ appeared\\ to\\ extend\\ to\\ the\\ gastric\\ cardia\\.\\ multiple\\ biopsies\\ were\\ obtained\\.\\ \ \(0\)\
\-\ a\\ malignant\\ esophageal\\ tumor\\ was\\ suspected\\ and\\ patient\\ subsequently\\ received\\ an\\ iv\\-contrast\\ enhanced\\ ct\\ of\\ the\\ chest\\,\\ abdomen\\,\\ and\\ pelvis\\ to\\ evaluate\\ for\\ any\\ metastatic\\ disease\\.\\ a\\ pet\\ scan\\ obtained\\ after\\ the\\ ct\\ test\\ did\\ not\\ show\\ evidence\\ of\\ lymphatic\\ or\\ hematogenous\\ metastases\ \(0\)\
\-\ iv\\ contrast\\ ct\\ of\\ chest\\,\\ abd\\,\\ pelvis\\:\ \(0\)\
\-\ a\\ 6\\.1x4\\.5cm\\ mass\\ that\\ extended\\ into\\ the\\ proximal\\ portion\\ of\\ the\\ stomach\\ was\\ noted\\ at\\ the\\ gatroesophageal\\ junction\\.\\ there\\ does\\ not\\ appear\\ to\\ be\\ any\\ obstruction\\ of\\ fluids\\ as\\ contrast\\ has\\ advanced\\ through\\ the\\ lesion\\ and\\ into\\ the\\ distal\\ bowel\\.\\ \ \(0\)\
\-\ there\\ is\\ a\\ 1\\.9cm\\ rounded\\ lesion\\ near\\ the\\ tail\\ of\\ the\\ pancreas\\ and\\ a\\ 1\\.0cm\\ enlarged\\ lymph\\ node\\ adjacent\\ to\\ the\\ portal\\ vein\\ that\\ is\\ concerning\\ for\\ metastatic\\ disease\\ and\\ \\ should\\ be\\ further\\ evaluated\\ by\\ a\\ pet\\ scan\\.\\ \ \(0\)\
\-\ there\\ are\\ multiple\\ hypodensities\\ in\\ the\\ liver\\ and\\ left\\ kidney\\ that\\ are\\ too\\ small\\ to\\ characterize\\ but\\ should\\ be\\ further\\ evaluated\\.\ \(0\)\
\-\ adenocarcinoma\ \(192\)\
\-\ lymphoma\ \(373\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ 2\\ week\\ h\\/o\\ of\\ dysphagia\\ to\\ solids\\ and\\ hematemesis\ \(1\)\
\-\ pmh\\:\\ htn\ \(0\)\
\-\ psh\\:\\ none\ \(0\)\
\-\ meds\\:\\ atenolol\ \(0\)\
\-\ all\\:\\ carbamazepine\ \(0\)\
\-\ sh\\:\\ no\\ tobacco\\ or\\ etoh\\ use\ \(0\)\
\-\ esophageal\\ cancer\\ is\\ the\\ 10th\\ leading\\ cause\\ of\\ deaths\\ due\\ to\\ cancer\\ in\\ the\\ united\\ states\\ and\\ continues\\ to\\ be\\ the\\ 19th\\ among\\ cancers\\ in\\ incidence\\.\\ the\\ two\\ main\\ types\\ are\\ squamous\\ cell\\ carcinoma\\ and\\ adenocarcinoma\\.\\ although\\ squamous\\ cell\\ constitutes\\ 95\\%\\ of\\ esophageal\\ cancers\\ worldwide\\,\\ adenocarcinoma\\ has\\ steadily\\ increased\\ to\\ be\\ the\\ major\\ histological\\ type\\ in\\ the\\ us\\ since\\ the\\ 1970s\\.\ \(0\)\
\-\ adenocarcinoma\\ affects\\ white\\ males\\ in\\ the\\ 6th\\ or\\ 7th\\ decade\\ and\\ is\\ most\\ commonly\\ located\\ in\\ the\\ distal\\ esophagus\\.\\ \\ risk\\ factors\\ include\\ gastroesophageal\\ reflux\\ disease\\ and\\ barrett\\‚\\Ä\\ôs\\ esophagus\\ where\\ there\\ is\\ replacement\\ of\\ normal\\ squamous\\ lining\\ with\\ intestinal\\-type\\ columnar\\ epithelium\\.\\ \\ interestingly\\,\\ these\\ histological\\ changes\\ were\\ found\\ in\\ patients\\ without\\ reflux\\ symptoms\\.\\ in\\ a\\ swedish\\ population\\-based\\ study\\,\\ 40\\%\\ of\\ patients\\ with\\ cancer\\ did\\ not\\ have\\ symptoms\\ at\\ least\\ weekly\\.\\ \\ in\\ comparison\\,\\ squamous\\ cell\\ cancer\\ of\\ esophagus\\ is\\ located\\ in\\ proximal\\-mid\\ esophagus\\,\\ affects\\ black\\ males\\,\\ and\\ is\\ commonly\\ associated\\ with\\ tobacco\\ and\\ alcohol\\ consumption\\.\\ \ \(0\)\
\-\ common\\ presenting\\ symptoms\\ of\\ esophageal\\ cancer\\ are\\ dysphagia\\,\\ weight\\ loss\\,\\ gerd\\ odynophagia\\,\\ and\\ dyspnea\\.\\ these\\ symptoms\\,\\ especially\\ any\\ evidence\\ of\\ mechanical\\ obstruction\\,\\ should\\ prompt\\ an\\ upper\\ endoscopy\\ where\\ biopsies\\ can\\ be\\ obtained\\.\\ the\\ primary\\ tumor\\ can\\ then\\ be\\ imaged\\ suing\\ ct\\ and\\ endoscopic\\ ultrasound\\.\\ ct\\ provides\\ a\\ general\\ overview\\ of\\ the\\ cancer\\ and\\ demonstrates\\ adjacent\\ organ\\ involvement\\,\\ although\\ esophageal\\ wall\\ layers\\ are\\ not\\ easily\\ distinguished\\.\\ eus\\ is\\ gaining\\ popularity\\ due\\ to\\ its\\ strength\\ in\\ visualizing\\ the\\ wall\\ layers\\.\\ its\\ drawbacks\\ include\\ operator\\ skill\\ and\\ viewing\\ \\‚\\Ä\\úhard\\ to\\ reach\\‚\\Ä\\ù\\ tumors\\.\\ \ \(0\)\
\-\ once\\ the\\ diagnosis\\ of\\ the\\ tumor\\ is\\ made\\,\\ imaging\\ to\\ rule\\ out\\ metastatic\\ disease\\ should\\ be\\ performed\\.\\ intravenous\\-contrast\\ enhanced\\ ct\\ of\\ the\\ chest\\,\\ abdomen\\,\\ and\\ pelvis\\ remains\\ the\\ gold\\ standard\\ although\\ sensitivity\\ is\\ dependent\\ on\\ the\\ size\\ of\\ the\\ lesion\\.\\ mri\\ and\\ us\\ modalities\\ can\\ be\\ used\\ to\\ further\\ characterize\\ metastatic\\ lesions\\.\\ positron\\ emission\\ tomography\\ is\\ a\\ new\\ tool\\ that\\ visualizes\\ the\\ higher\\ rate\\ of\\ glucose\\ uptake\\ by\\ malignant\\ tissue\\ versus\\ normal\\,\\ thus\\,\\ providing\\ more\\ information\\ about\\ metastatic\\ disease\\.\\ \ \(0\)\
\-\ appropriate\\ imaging\\ allows\\ clinicians\\ to\\ properly\\ stage\\ the\\ tumor\\,\\ which\\ directly\\ affects\\ the\\ treatment\\ options\\ and\\ prognosis\\.\\ well\\ localized\\ tumors\\ can\\ be\\ resected\\ and\\ have\\ the\\ best\\ 5\\-year\\ survival\\ of\\ 65\\-85\\%\\.\\ more\\ invasive\\ tumors\\ and\\ those\\ with\\ distant\\ metastses\\ are\\ not\\ surgical\\ candidates\\ and\\ are\\ treated\\ with\\ combined\\ chemotherapy\\ and\\ radiation\\ therapy\\ for\\ palliation\\.\\ the\\ overall\\ 5yr\\ survival\\ of\\ esophageal\\ cancer\\ is\\ 12\\-15\\%\\.\ \(0\)\
\-\ references\ \(24\)\
\-\ elton\\,\\ eric\\.\\ \\‚\\Ä\\úesophageal\\ cancer\\,\\‚\\Ä\\ù\\ disease\\-a\\-mouth\\,\\ v51\\,\\ n12\\ \\(2005\\)\\ 664\\-684\\.\ \(0\)\
\-\ korst\\,\\ r\\ and\\ altorki\\,n\\.\\ \\‚\\Ä\\úimaging\\ for\\ esophageal\\ tumors\\,\\‚\\Ä\\ù\\ radiologic\\ clinics\\ of\\ north\\ america\\ 43\\(2005\\)\\ 611\\-619\\.\ \(0\)\
\-\ patel\\,\\ a\\ and\\ buenaventura\\,\\ p\\.\\ \\‚\\Ä\\úcurrent\\ staging\\ of\\ esophageal\\ carcinoma\\,\\‚\\Ä\\ù\\ surgical\\ clinics\\ of\\ north\\ america\\ 85\\ \\(2005\\)\\ 555\\-567\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ esophageal\\:\\ 0\\.04670080478958978\ \(0\)\
\-\ cancer\\:\\ 0\\.029765989556182943\ \(0\)\
\-\ esophagus\\:\\ 0\\.024566708278582237\ \(0\)\
\-\ squamous\\:\\ 0\\.02214987780522841\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.019557904342056898\ \(0\)\
\-\ affects\\:\\ 0\\.019328243862457233\ \(0\)\
\-\ 2005\\:\\ 0\\.018321162137386222\ \(0\)\
\-\ be\\:\\ 0\\.017453731435018927\ \(0\)\
\-\ metastatic\\:\\ 0\\.01709490916780999\ \(0\)\
\-\ tumors\\:\\ 0\\.017005119775737754\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.016908614133929325\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.01681383498293184\ \(0\)\
\-\ characterize\\:\\ 0\\.016769832514380127\ \(0\)\
\-\ clinics\\:\\ 0\\.016557798851668772\ \(0\)\
\-\ america\\:\\ 0\\.015287406586074371\ \(0\)\
\-\ north\\:\\ 0\\.015046421743145294\ \(0\)\
\-\ biopsies\\:\\ 0\\.01462167300122429\ \(0\)\
\-\ should\\:\\ 0\\.014432892937159205\ \(0\)\
\-\ histological\\:\\ 0\\.014090095000000047\ \(0\)\
\-\ layers\\:\\ 0\\.014090095000000047\ \(0\)\
\-\ tobacco\\:\\ 0\\.01364756762340888\ \(0\)\
\-\ cancers\\:\\ 0\\.01364756762340888\ \(0\)\
\-\ males\\:\\ 0\\.01304290894266456\ \(0\)\
\-\ pelvis\\:\\ 0\\.01233811154937071\ \(0\)\
\-\ survival\\:\\ 0\\.0121361905148854\ \(0\)\
\-\ obtained\\:\\ 0\\.012070991128783478\ \(0\)\
\-\ pet\\:\\ 0\\.011880225387232232\ \(0\)\
\-\ \\,\\:\\ 0\\.011832360479563556\ \(0\)\
\-\ 13\\.1\\/39\\.5\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ iv\\-contrast\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ 6\\.1x4\\.5cm\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ 1\\.0cm\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ carbamazepine\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ 19th\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ 1970s\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ intestinal\\-type\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ swedish\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ proximal\\-mid\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ suing\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ popularity\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ drawbacks\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ intravenous\\-contrast\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ visualizes\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ 65\\-85\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ metastses\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ elton\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ disease\\-a\\-mouth\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ v51\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ n12\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ 664\\-684\\.\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ korst\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ altorki\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ 611\\-619\\.\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ buenaventura\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ 555\\-567\\:\\ 0\\.011676183343001984\ \(0\)\
\-\ although\\:\\ 0\\.011467268664542797\ \(0\)\
\-\ symptoms\\:\\ 0\\.011282953519990141\ \(0\)\
\-\ disease\\:\\ 0\\.011099900989793675\ \(0\)\
\-\ dysphagia\\:\\ 0\\.011023994897507218\ \(0\)\
\-\ are\\:\\ 0\\.010800155109545977\ \(0\)\
\-\ further\\:\\ 0\\.010797791291921556\ \(0\)\
\-\ gatroesophageal\\:\\ 0\\.010758107607160998\ \(0\)\
\-\ eus\\:\\ 0\\.010758107607160998\ \(0\)\
\-\ any\\:\\ 0\\.010692059734062094\ \(0\)\
\-\ \\%\\:\\ 0\\.010560641236270239\ \(0\)\
\-\ tumor\\:\\ 0\\.01055487312111688\ \(0\)\
\-\ received\\:\\ 0\\.01052008301326598\ \(0\)\
\-\ \\:\\:\\ 0\\.010479369154880338\ \(0\)\
\-\ reflux\\:\\ 0\\.010458235691419644\ \(0\)\
\-\ evaluated\\:\\ 0\\.010377956619908838\ \(0\)\
\-\ can\\:\\ 0\\.01026872769520037\ \(0\)\
\-\ constitutes\\:\\ 0\\.010221067728872038\ \(0\)\
\-\ skill\\:\\ 0\\.010221067728872038\ \(0\)\
\-\ 5yr\\:\\ 0\\.010221067728872038\ \(0\)\
\-\ gaining\\:\\ 0\\.00984003187132001\ \(0\)\
\-\ 12\\-15\\:\\ 0\\.00984003187132001\ \(0\)\
\-\ patel\\:\\ 0\\.00984003187132001\ \(0\)\
\-\ enhanced\\:\\ 0\\.009685995032455548\ \(0\)\
\-\ eric\\:\\ 0\\.009544477498718408\ \(0\)\
\-\ ct\\:\\ 0\\.009499101881261268\ \(0\)\
\-\ us\\:\\ 0\\.009495125316852746\ \(0\)\
\-\ located\\:\\ 0\\.009317088893823738\ \(0\)\
\-\ amylase\\/lipase\\:\\ 0\\.00930299199303105\ \(0\)\
\-\ 1\\.9cm\\:\\ 0\\.00930299199303105\ \(0\)\
\-\ atenolol\\:\\ 0\\.00930299199303105\ \(0\)\
\-\ deaths\\:\\ 0\\.00930299199303105\ \(0\)\
\-\ columnar\\:\\ 0\\.00930299199303105\ \(0\)\
\-\ population\\-based\\:\\ 0\\.00930299199303105\ \(0\)\
\-\ visualizing\\:\\ 0\\.00930299199303105\ \(0\)\
\-\ operator\\:\\ 0\\.00930299199303105\ \(0\)\
\-\ where\\:\\ 0\\.009238787430932231\ \(0\)\
\-\ cell\\:\\ 0\\.009171817397012528\ \(0\)\
\-\ fungating\\:\\ 0\\.009098818907167133\ \(0\)\
\-\ overview\\:\\ 0\\.009098818907167133\ \(0\)\
\-\ positron\\:\\ 0\\.009098818907167133\ \(0\)\
\-\ is\\:\\ 0\\.008937071974326765\ \(0\)\
\-\ cardia\\:\\ 0\\.008921956135479022\ \(0\)\
\-\ worldwide\\:\\ 0\\.008921956135479022\ \(0\)\
\-\ steadily\\:\\ 0\\.008921956135479022\ \(0\)\
\-\ palliation\\:\\ 0\\.008921956135479022\ \(0\)\
\-\ normal\\:\\ 0\\.008871605659596696\ \(0\)\
\-\ sh\\:\\ 0\\.008765952114742091\ \(0\)\
\-\ consumption\\:\\ 0\\.008765952114742091\ \(0\)\
\-\ viewing\\:\\ 0\\.008765952114742091\ \(0\)\
\-\ hematemesis\\:\\ 0\\.00862640176287742\ \(0\)\
\-\ barrett\\:\\ 0\\.00862640176287742\ \(0\)\
\-\ tool\\:\\ 0\\.00862640176287742\ \(0\)\
\-\ commonly\\:\\ 0\\.008541805148226864\ \(0\)\
\-\ its\\:\\ 0\\.008541805148226864\ \(0\)\
\-\ thirds\\:\\ 0\\.008500163114129971\ \(0\)\
\-\ hypodensities\\:\\ 0\\.008500163114129971\ \(0\)\
\-\ 10th\\:\\ 0\\.008500163114129971\ \(0\)\
\-\ reach\\:\\ 0\\.008500163114129971\ \(0\)\
\-\ candidates\\:\\ 0\\.008500163114129971\ \(0\)\
\-\ to\\:\\ 0\\.008484796856483172\ \(0\)\
\-\ emission\\:\\ 0\\.008384916257190064\ \(0\)\
\-\ 5\\-year\\:\\ 0\\.008278899425834386\ \(0\)\
\-\ malignant\\:\\ 0\\.008181909076501459\ \(0\)\
\-\ not\\:\\ 0\\.00817760709762871\ \(0\)\
\-\ did\\:\\ 0\\.008173294413226288\ \(0\)\
\-\ chest\\:\\ 0\\.008124750993606034\ \(0\)\
\-\ psh\\:\\ 0\\.008003880399638036\ \(0\)\
\-\ weekly\\:\\ 0\\.008003880399638036\ \(0\)\
\-\ odynophagia\\:\\ 0\\.008003880399638036\ \(0\)\
\-\ providing\\:\\ 0\\.008003880399638036\ \(0\)\
\-\ clinicians\\:\\ 0\\.008003880399638036\ \(0\)\
\-\ obstruction\\:\\ 0\\.007982516685005128\ \(0\)\
\-\ imaging\\:\\ 0\\.007955260229624912\ \(0\)\
\-\ h\\/h\\:\\ 0\\.007923582887298388\ \(0\)\
\-\ solids\\:\\ 0\\.007847876378901105\ \(0\)\
\-\ 7th\\:\\ 0\\.007847876378901105\ \(0\)\
\-\ properly\\:\\ 0\\.007847876378901105\ \(0\)\
\-\ that\\:\\ 0\\.00781976544931827\ \(0\)\
\-\ egd\\:\\ 0\\.007708326027036433\ \(0\)\
\-\ distinguished\\:\\ 0\\.007643703293037186\ \(0\)\
\-\ chem\\:\\ 0\\.007523210871572647\ \(0\)\
\-\ lymphatic\\:\\ 0\\.007523210871572647\ \(0\)\
\-\ interestingly\\:\\ 0\\.007523210871572647\ \(0\)\
\-\ lfts\\:\\ 0\\.007466840521349076\ \(0\)\
\-\ fluids\\:\\ 0\\.007466840521349076\ \(0\)\
\-\ lining\\:\\ 0\\.007466840521349076\ \(0\)\
\-\ gold\\:\\ 0\\.007466840521349076\ \(0\)\
\-\ etoh\\:\\ 0\\.007412771654434831\ \(0\)\
\-\ 6th\\:\\ 0\\.007412771654434831\ \(0\)\
\-\ epithelium\\:\\ 0\\.007412771654434831\ \(0\)\
\-\ hematogenous\\:\\ 0\\.007310836500612145\ \(0\)\
\-\ adjacent\\:\\ 0\\.0071571821036669325\ \(0\)\
\-\ the\\:\\ 0\\.007141353779392591\ \(0\)\
\-\ provides\\:\\ 0\\.0070055071514574\ \(0\)\
\-\ meds\\:\\ 0\\.006967113062883556\ \(0\)\
\-\ united\\:\\ 0\\.006967113062883556\ \(0\)\
\-\ prompt\\:\\ 0\\.006967113062883556\ \(0\)\
\-\ imaged\\:\\ 0\\.006967113062883556\ \(0\)\
\-\ allows\\:\\ 0\\.006967113062883556\ \(0\)\
\-\ lesion\\:\\ 0\\.006916113480796508\ \(0\)\
\-\ gastroesophageal\\:\\ 0\\.006893510611022879\ \(0\)\
\-\ circumferential\\:\\ 0\\.006858188429457103\ \(0\)\
\-\ gerd\\:\\ 0\\.00682378381170444\ \(0\)\
\-\ obstructing\\:\\ 0\\.006790250291195446\ \(0\)\
\-\ modalities\\:\\ 0\\.006790250291195446\ \(0\)\
\-\ there\\:\\ 0\\.006737565862066165\ \(0\)\
\-\ among\\:\\ 0\\.006725627557196198\ \(0\)\
\-\ abdomen\\:\\ 0\\.006705653676544891\ \(0\)\
\-\ in\\:\\ 0\\.006697704320110012\ \(0\)\
\-\ panel\\:\\ 0\\.006664011642447996\ \(0\)\
\-\ decade\\:\\ 0\\.006664011642447996\ \(0\)\
\-\ endoscopic\\:\\ 0\\.006664011642447996\ \(0\)\
\-\ organ\\:\\ 0\\.006634246270458515\ \(0\)\
\-\ distant\\:\\ 0\\.00660513513573166\ \(0\)\
\-\ n\\:\\ 0\\.0065766500957038935\ \(0\)\
\-\ wall\\:\\ 0\\.006556712901294692\ \(0\)\
\-\ extended\\:\\ 0\\.0065487647855080895\ \(0\)\
\-\ endoscopy\\:\\ 0\\.0065487647855080895\ \(0\)\
\-\ black\\:\\ 0\\.00652145447133228\ \(0\)\
\-\ staging\\:\\ 0\\.00652145447133228\ \(0\)\
\-\ two\\:\\ 0\\.006482996655936439\ \(0\)\
\-\ and\\:\\ 0\\.00643740815201311\ \(0\)\
\-\ carcinoma\\:\\ 0\\.006415702437128123\ \(0\)\
\-\ sensitivity\\:\\ 0\\.006392760764771157\ \(0\)\
\-\ 95\\:\\ 0\\.006368457269846394\ \(0\)\
\-\ include\\:\\ 0\\.006350075464980892\ \(0\)\
\-\ too\\:\\ 0\\.006344591699644171\ \(0\)\
\-\ scan\\:\\ 0\\.0063371429415443135\ \(0\)\
\-\ 85\\:\\ 0\\.006321148551168143\ \(0\)\
\-\ mass\\:\\ 0\\.0062964821560135865\ \(0\)\
\-\ mechanical\\:\\ 0\\.006253210412906487\ \(0\)\
\-\ easily\\:\\ 0\\.006253210412906487\ \(0\)\
\-\ combined\\:\\ 0\\.006253210412906487\ \(0\)\
\-\ tail\\:\\ 0\\.00623131729773932\ \(0\)\
\-\ htn\\:\\ 0\\.00623131729773932\ \(0\)\
\-\ hard\\:\\ 0\\.00623131729773932\ \(0\)\
\-\ directly\\:\\ 0\\.006209780184001863\ \(0\)\
\-\ appeared\\:\\ 0\\.006167728927956061\ \(0\)\
\-\ information\\:\\ 0\\.006167728927956061\ \(0\)\
\-\ distal\\:\\ 0\\.006154380368068945\ \(0\)\
\-\ dependent\\:\\ 0\\.006107054045795407\ \(0\)\
\-\ 43\\:\\ 0\\.006107054045795407\ \(0\)\
\-\ tomography\\:\\ 0\\.0060490373270425685\ \(0\)\
\-\ glucose\\:\\ 0\\.0060490373270425685\ \(0\)\
\-\ due\\:\\ 0\\.006040469279345271\ \(0\)\
\-\ abd\\:\\ 0\\.005993455606381599\ \(0\)\
\-\ portal\\:\\ 0\\.005957656040304885\ \(0\)\
\-\ concerning\\:\\ 0\\.005940112693616116\ \(0\)\
\-\ evidence\\:\\ 0\\.005934947240706961\ \(0\)\
\-\ h\\/o\\:\\ 0\\.005905708075863453\ \(0\)\
\-\ continues\\:\\ 0\\.005905708075863453\ \(0\)\
\-\ these\\:\\ 0\\.005890979316444609\ \(0\)\
\-\ comparison\\:\\ 0\\.005888835194039042\ \(0\)\
\-\ remains\\:\\ 0\\.005888835194039042\ \(0\)\
\-\ radiologic\\:\\ 0\\.005888835194039042\ \(0\)\
\-\ patients\\:\\ 0\\.005858475759910002\ \(0\)\
\-\ p\\:\\ 0\\.005807551821355211\ \(0\)\
\-\ advanced\\:\\ 0\\.00579187704301481\ \(0\)\
\-\ pancreas\\:\\ 0\\.00579187704301481\ \(0\)\
\-\ once\\:\\ 0\\.00579187704301481\ \(0\)\
\-\ standard\\:\\ 0\\.00579187704301481\ \(0\)\
\-\ a\\:\\ 0\\.005778275258284257\ \(0\)\
\-\ types\\:\\ 0\\.005776385599619855\ \(0\)\
\-\ alcohol\\:\\ 0\\.005701534989999535\ \(0\)\
\-\ invasive\\:\\ 0\\.005687059399890673\ \(0\)\
\-\ extend\\:\\ 0\\.005672740305712904\ \(0\)\
\-\ least\\:\\ 0\\.005672740305712904\ \(0\)\
\-\ more\\:\\ 0\\.005661394196853421\ \(0\)\
\-\ pmh\\:\\ 0\\.005630689049667102\ \(0\)\
\-\ thus\\:\\ 0\\.005630689049667102\ \(0\)\
\-\ overall\\:\\ 0\\.005630689049667102\ \(0\)\
\-\ resected\\:\\ 0\\.005603378735491293\ \(0\)\
\-\ rounded\\:\\ 0\\.005576620182752856\ \(0\)\
\-\ higher\\:\\ 0\\.0055503915373274525\ \(0\)\
\-\ replacement\\:\\ 0\\.005524672218311425\ \(0\)\
\-\ localized\\:\\ 0\\.005511997448753609\ \(0\)\
\-\ options\\:\\ 0\\.005499442820999247\ \(0\)\
\-\ lumen\\:\\ 0\\.0054503815340054065\ \(0\)\
\-\ leading\\:\\ 0\\.00541474252351544\ \(0\)\
\-\ into\\:\\ 0\\.0053862950144628\ \(0\)\
\-\ versus\\:\\ 0\\.005380037394516733\ \(0\)\
\-\ prognosis\\:\\ 0\\.005368668197574492\ \(0\)\
\-\ dyspnea\\:\\ 0\\.005357395760928256\ \(0\)\
\-\ appropriate\\:\\ 0\\.0053351346770655\ \(0\)\
\-\ states\\:\\ 0\\.005324142885257956\ \(0\)\
\-\ current\\:\\ 0\\.005302429229925934\ \(0\)\
\-\ major\\:\\ 0\\.005291704448160876\ \(0\)\
\-\ main\\:\\ 0\\.005270511943066252\ \(0\)\
\-\ incidence\\:\\ 0\\.005188978309954419\ \(0\)\
\-\ partially\\:\\ 0\\.0051791306563285676\ \(0\)\
\-\ node\\:\\ 0\\.0051791306563285676\ \(0\)\
\-\ those\\:\\ 0\\.005150019521601714\ \(0\)\
\-\ r\\:\\ 0\\.005140456279252724\ \(0\)\
\-\ were\\:\\ 0\\.00513983135546999\ \(0\)\
\-\ subsequently\\:\\ 0\\.0051309615912015815\ \(0\)\
\-\ factors\\:\\ 0\\.005084483021915131\ \(0\)\
\-\ contrast\\:\\ 0\\.005066955461742796\ \(0\)\
\-\ gastric\\:\\ 0\\.005057359139340905\ \(0\)\
\-\ strength\\:\\ 0\\.005022036957775128\ \(0\)\
\-\ stomach\\:\\ 0\\.005004722942454132\ \(0\)\
\-\ have\\:\\ 0\\.004901822724145939\ \(0\)\
\-\ near\\:\\ 0\\.004897383591456614\ \(0\)\
\-\ suspected\\:\\ 0\\.0048738013071738225\ \(0\)\
\-\ test\\:\\ 0\\.004835407218599979\ \(0\)\
\-\ metastases\\:\\ 0\\.004835407218599979\ \(0\)\
\-\ stage\\:\\ 0\\.004827860170766022\ \(0\)\
\-\ general\\:\\ 0\\.004768983664049685\ \(0\)\
\-\ multiple\\:\\ 0\\.004767698022461639\ \(0\)\
\-\ 40\\:\\ 0\\.004761804766739303\ \(0\)\
\-\ best\\:\\ 0\\.004761804766739303\ \(0\)\
\-\ surgical\\:\\ 0\\.004758203364904513\ \(0\)\
\-\ junction\\:\\ 0\\.004740498624021919\ \(0\)\
\-\ rule\\:\\ 0\\.004726482585173526\ \(0\)\
\-\ references\\:\\ 0\\.00470573276167101\ \(0\)\
\-\ an\\:\\ 0\\.004695357076628066\ \(0\)\
\-\ especially\\:\\ 0\\.004658544446911869\ \(0\)\
\-\ appear\\:\\ 0\\.004632315801486466\ \(0\)\
\-\ presenting\\:\\ 0\\.0046129796433127535\ \(0\)\
\-\ evaluate\\:\\ 0\\.0045751341168967855\ \(0\)\
\-\ lymph\\:\\ 0\\.004568930342973042\ \(0\)\
\-\ third\\:\\ 0\\.004538339992251652\ \(0\)\
\-\ made\\:\\ 0\\.004508440227962197\ \(0\)\
\-\ uptake\\:\\ 0\\.004496666787674453\ \(0\)\
\-\ use\\:\\ 0\\.004473429291448083\ \(0\)\
\-\ rate\\:\\ 0\\.004411551643014362\ \(0\)\
\-\ about\\:\\ 0\\.004362990074310268\ \(0\)\
\-\ used\\:\\ 0\\.004341965770792002\ \(0\)\
\-\ has\\:\\ 0\\.004250860848991464\ \(0\)\
\-\ which\\:\\ 0\\.00422554857547695\ \(0\)\
\-\ since\\:\\ 0\\.004157304134699624\ \(0\)\
\-\ involvement\\:\\ 0\\.0041482631213613464\ \(0\)\
\-\ iv\\:\\ 0\\.004130364155577607\ \(0\)\
\-\ portion\\:\\ 0\\.004099611453455744\ \(0\)\
\-\ risk\\:\\ 0\\.004099611453455744\ \(0\)\
\-\ vein\\:\\ 0\\.004095275923197506\ \(0\)\
\-\ weight\\:\\ 0\\.004056881834623663\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.004056881834623663\ \(0\)\
\-\ then\\:\\ 0\\.004027770699896808\ \(0\)\
\-\ of\\:\\ 0\\.004012051418208873\ \(0\)\
\-\ kidney\\:\\ 0\\.003987262854370874\ \(0\)\
\-\ or\\:\\ 0\\.003979560591908771\ \(0\)\
\-\ involving\\:\\ 0\\.0039714003496732365\ \(0\)\
\-\ new\\:\\ 0\\.003944090035497429\ \(0\)\
\-\ was\\:\\ 0\\.0039269305518424644\ \(0\)\
\-\ liver\\:\\ 0\\.0039022801467983093\ \(0\)\
\-\ for\\:\\ 0\\.003862824628570676\ \(0\)\
\-\ does\\:\\ 0\\.0038617497620980217\ \(0\)\
\-\ enlarged\\:\\ 0\\.0038617497620980217\ \(0\)\
\-\ week\\:\\ 0\\.0038437290308983153\ \(0\)\
\-\ cause\\:\\ 0\\.0038294869225853857\ \(0\)\
\-\ \\(\\:\\ 0\\.0038270819933449566\ \(0\)\
\-\ type\\:\\ 0\\.0038153963289363053\ \(0\)\
\-\ size\\:\\ 0\\.003794537577985128\ \(0\)\
\-\ \\)\\:\\ 0\\.0037803321436466497\ \(0\)\
\-\ by\\:\\ 0\\.0037691944456817875\ \(0\)\
\-\ white\\:\\ 0\\.003753780414188103\ \(0\)\
\-\ out\\:\\ 0\\.003740468711070882\ \(0\)\
\-\ study\\:\\ 0\\.0037240150421986216\ \(0\)\
\-\ radiation\\:\\ 0\\.003714240065645479\ \(0\)\
\-\ found\\:\\ 0\\.003566921343645182\ \(0\)\
\-\ bowel\\:\\ 0\\.0035496073283241844\ \(0\)\
\-\ show\\:\\ 0\\.0034743787211809615\ \(0\)\
\-\ proximal\\:\\ 0\\.00339807043934704\ \(0\)\
\-\ treated\\:\\ 0\\.0033878819020978267\ \(0\)\
\-\ \\‚\\Ä\\ô\\:\\ 0\\.0033828168737025906\ \(0\)\
\-\ ultrasound\\:\\ 0\\.0033577782582864943\ \(0\)\
\-\ primary\\:\\ 0\\.0033528268382724455\ \(0\)\
\-\ demonstrated\\:\\ 0\\.003321086069479427\ \(0\)\
\-\ loss\\:\\ 0\\.003285383009891973\ \(0\)\
\-\ s\\:\\ 0\\.003246049890217996\ \(0\)\
\-\ changes\\:\\ 0\\.0032437721539537224\ \(0\)\
\-\ lymphoma\\:\\ 0\\.003234700177999319\ \(0\)\
\-\ through\\:\\ 0\\.0032145126071799583\ \(0\)\
\-\ all\\:\\ 0\\.003201223164809657\ \(0\)\
\-\ performed\\:\\ 0\\.0031557328890428065\ \(0\)\
\-\ low\\:\\ 0\\.0031472424541276814\ \(0\)\
\-\ at\\:\\ 0\\.0030669222591566438\ \(0\)\
\-\ lesions\\:\\ 0\\.003029881465356222\ \(0\)\
\-\ therapy\\:\\ 0\\.003026014299656441\ \(0\)\
\-\ common\\:\\ 0\\.0029619433270945657\ \(0\)\
\-\ none\\:\\ 0\\.0028075755058384194\ \(0\)\
\-\ increased\\:\\ 0\\.002768854015628683\ \(0\)\
\-\ upper\\:\\ 0\\.002731232457442011\ \(0\)\
\-\ noted\\:\\ 0\\.0026826770707981374\ \(0\)\
\-\ tissue\\:\\ 0\\.0026826770707981374\ \(0\)\
\-\ associated\\:\\ 0\\.002670811340275102\ \(0\)\
\-\ without\\:\\ 0\\.002664918101136636\ \(0\)\
\-\ most\\:\\ 0\\.0026130266777855313\ \(0\)\
\-\ small\\:\\ 0\\.002607384482623998\ \(0\)\
\-\ mri\\:\\ 0\\.0026003653707478407\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0025989660010336687\ \(0\)\
\-\ well\\:\\ 0\\.002560372123137286\ \(0\)\
\-\ lower\\:\\ 0\\.0025455126746541227\ \(0\)\
\-\ large\\:\\ 0\\.0024748906381868606\ \(0\)\
\-\ demonstrates\\:\\ 0\\.002472345962454551\ \(0\)\
\-\ 2\\:\\ 0\\.002437224498689465\ \(0\)\
\-\ but\\:\\ 0\\.002413911656998063\ \(0\)\
\-\ after\\:\\ 0\\.0023417234471645064\ \(0\)\
\-\ treatment\\:\\ 0\\.0022908833901998504\ \(0\)\
\-\ patient\\:\\ 0\\.0022691176977917564\ \(0\)\
\-\ as\\:\\ 0\\.0017120231866147389\ \(0\)\
\-\ \\.\\:\\ 0\\.001645673858817377\ \(0\)\
\-\ this\\:\\ 0\\.0012730294216081232\ \(0\)\
\-\ left\\:\\ 0\\.0012663645950634632\ \(0\)\
\-\ no\\:\\ 0\\.0011396611267600026\ \(0\)\
\-\ on\\:\\ 0\\.0009587960428681166\ \(0\)\
\-\ with\\:\\ 0\\.000774862093310528\ \(0\)\
